MSFT 425.025 -0.9035% AAPL 220.43 0.8648% NVDA 115.85 1.4004% GOOGL 172.44 -0.1101% GOOG 174.27 -0.0573% AMZN 182.99 1.1945% META 460.09 -0.2558% AVGO 152.64 0.859% TSLA 224.8499 4.102% TSM 161.61 1.1327% LLY 823.56 -4.2238% V 257.56 1.3338% JPM 209.535 0.453% UNH 562.83 0.5502% NVO 129.31 -1.7401% WMT 70.206 -0.5581% LVMUY 143.15 0.9022% XOM 116.85 1.5999% LVMHF 714.04 0.4982% MA 436.96 1.0429%
Neurocrine Biosciences, Inc.
NBIX Details
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is a neuroscience-focused biopharmaceutical company engaged in researching and developing innovative therapies for patients with severe neurological, endocrine, and psychiatric disorders. The company's commercial products include INGREZZA (for the treatment of tardive dyskinesia), ONGENTYS (for Parkinson's disease), ORILISSA (for severe pain associated with endometriosis), and ORIAHNN (for uterine fibroids). NBIX developed ORILISSA and ORIAHNN in collaboration with AbbVie Inc. As of January 31, 2022, the company's market capitalization stood at USD 7.28 billion.
Latest News:
9MFY21Results:
Key Risks:
Outlook:
Valuation Methodology: EV / Sales Multiple Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
Stock Recommendation:
NBIX's stock price has fallen 25.61% in the past three months and is currently trading around the lower band of its 52-week range of USD 71.88 to USD 119.99. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 93.70.
Considering the company's growth prospects, solid track record, favourable results from valbenazine, and associated risks, we recommend a "Buy" rating on the stock at the closing price of USD 79.02, up 2.98% as of January 31, 2022.
Three-Year Technical Price Chart (as of January 31, 2022). Source: REFINITIV, Analysis by Kalkine Group
Technical Analysis Summary:
Technical Indicators Defined: -
Support: A level where-in the stock prices tend to find support if they are falling, and downtrend may take a pause backed by demand or buying interest.
Resistance: A level where-in the stock prices tend to find resistance when they are rising, and uptrend may take a pause due to profit booking or selling interest.
Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.
Note 1: The reference data in this report has been partly sourced from REFINITIV.
Note 2: Investment decision should be made depending on the investors' appetite on upside potential, risks, holding duration, and any previous holdings. Investors can consider exiting from the stock if the Target Price mentioned as per the valuation has been achieved and subject to the factors discussed above.
Tutor Perini Corporation
TPC Details
Tutor Perini Corporation (NYSE: TPC) provides private and public general contracting, construction management, and design-build services. The firm builds and restores transportation infrastructure, water-treatment facilities, and various buildings. It organizes and plans the people, equipment, materials, and subcontractors needed for a project. TPC has three operating segments: civil, building, and specialist contractors, with the civil business accounting for the most revenue. As of January 31, 2022, the company's market capitalization stood at USD 619.00 million.
Latest News:
Q3FY21 Results:
Key Risks:
Outlook:
Valuation Methodology: EV/EBITDA Multiple Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
Stock Recommendation:
TPC's stock price has declined 31.21% in the past nine months and is currently leaning towards the lower band of its 52-week range of USD 11.00 to USD 20.24. The stock is currently trading below its 50 and 200 DMA levels, and its RSI Index is at 42.90. We have valued the stock using the EV/EBITDA-based relative valuation methodology and arrived at a target price of USD 14.70.
Considering the correction in the stock price in the past nine months, recent commercial contracts, robust backlog, fostering outlook, and associated risks, we recommend a "Speculative Buy" rating on the stock at the closing price of USD 11.90, down 1.82% as of January 31, 2022.
Three-Year Technical Price Chart (as of January 31, 2022). Analysis by Kalkine Group
Technical Analysis Summary:
Technical Indicators Defined: -
Support: A level where-in the stock prices tend to find support if they are falling, and downtrend may take a pause backed by demand or buying interest.
Resistance: A level where-in the stock prices tend to find resistance when they are rising, and uptrend may take a pause due to profit booking or selling interest.
Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.
Note 1: The reference data in this report has been partly sourced from REFINITIV.
Note 2: Investment decision should be made depending on the investors' appetite on upside potential, risks, holding duration, and any previous holdings. Investors can consider exiting from the stock if the Target Price mentioned as per the valuation has been achieved and subject to the factors discussed above.